The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 6, 2014, Pages 1273-1283

  Azijli, Kaamar ^a   Van Roosmalen, Ingrid A M ^a   Smit, Jorn ^b   Pillai, Saravanan ^a   Fukushima, Masakazu ^c   De Jong, Steven ^a   Peters, Godefridus J ^b   Bijnsdorp, Irene V ^b   Kruyt, Frank A E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Apoptosis; NSCLC; Synergy; TFT; TRAIL

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; FLICE INHIBITORY PROTEIN; PROTEIN BAX; PROTEIN P53; TRIFLURIDINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL LINE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CYTOTOXICITY; DOWN REGULATION; DRUG POTENTIATION; FLOW CYTOMETRY; GROWTH INHIBITION; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; SURFACE PROPERTY; WESTERN BLOTTING;

ANTIMETABOLITES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASES; CATHEPSIN B; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; THYMIDYLATE SYNTHASE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRIFLURIDINE;

EID: 84903820636     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2465-1     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57(1):43-66 (Pubitemid 46148091)
2. Mountain CF (1995) New prognostic factors in lung cancer. Biologic prophets of cancer cell aggression. Chest 108(1):246-254
3. Ashkenazi A (2008) Directing cancer cells to self-destruct with proapoptotic receptor agonists. Nat Rev Drug Discov 7(12):1001-1012
4. Wang S, El-Deiry WS (2003) TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22(53):8628-8633 (Pubitemid 38019198)
5. Danial N, Korsmeyer SJ (2004) Cell death: critical control points. Cell 116(2):205-219 (Pubitemid 38167313)
6. Voortman J, Resende TP, Abou El Hassan MA, Giaccone G, Kruyt FA (2007) TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther 6(7):2103-2112 (Pubitemid 47052501)
7. Pore MM, Hiltermann TJ, Kruyt FA (2010) Targeting apoptosis pathways in lung cancer. Cancer Lett 332(2):359-368
8. Bagnoli M, Canevari S, Mezzanzanica D (2010) Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. Int J Biochem Cell Biol 42(2):210-213
9. Stegehuis JH, de Wilt LH, de Vries EG, Groen HJ, de Jong S, Kruyt FA (2010) TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives. Drug Resist Updat 13(1-2):2-15
10. Temmink OH, Emura T, de Bruin M, Fukushima M, Peters GJ (2007) Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci 98(6):779-789 (Pubitemid 46691813)
11. Bijnsdorp IV, Peters GJ, Temmink OH, Fukushima M, Kruyt FA (2010) Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells. Int J Cancer 126(10):2457-2468
12. Broker LE, Kruyt FA, Giaccone G (2005) Cell death independent of caspases: a review. Clin Cancer Res 11(9):3155-3162 (Pubitemid 40627860)
13. Emura T, Murakami Y, Nakagawa F, Fukushima M, Kitazato K (2004) A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med 13(4):545-549
14. Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abbruzzese JL (2008) Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs 26(5):445-454
15. Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Sugimoto N, Tsuji Y, Moriwaki T, Esaki T, Hamada C, Tanase T, Ohtsu A (2012) TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13(10):993-1001
16. Keepers YP, Pizao PE, Peters GJ, van Ark-Otte J, Winograd B, Pinedo HM (1991) Comparison of the sulforhodamine B protein and tetrazolium (MT) assays for in vitro chemosensitivity testing. Eur J Cancer 27(7):897-900
17. Bijnsdorp IV, Kruyt FA, Gokoel S, Fukushima M, Peters GJ (2008) Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent. Cancer Sci 99(11):2302-2308
18. Bijnsdorp IV, Capriotti F, Kruyt FA, Losekoot N, Fukushima M, Griffioen AW, Thijssen VL, Peters GJ (2011) Thymidine phosphorylase in cancer cells stimulates human endothelial cell migration and invasion by the secretion of angiogenic factors. Br J Cancer 104(7):1185-1192
19. Mathews ST, Plaisance EP, Kim T (2009) Imaging systems for westerns: chemiluminescence vs. infrared detection. Methods Mol Biol 536:499-513
20. Koyama S, Koike N, Adachi S (2002) Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor. J Cancer Res Clin Oncol 128(2):73-79 (Pubitemid 34117828)
21. Duiker EW, Meijer A, van der Bilt AR, Meersma GJ, Kooi N, van der Zee AG, de Vries EG, de Jong S (2011) Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. Br J Cancer 104(8):1278-1287
22. Kastan MB, Bartek J (2004) Cell-cycle checkpoints and cancer. Nature 432(7015):316-323 (Pubitemid 39551659)
23. Mendoza FJ, Ishdorj G, Hu X, Gibson SB (2008) Death receptor-4 (DR4) expression is regulated by transcription factor NF-kappaB in response to etoposide treatment. Apoptosis 13(6):756-770
24. Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA (2006) Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Cancer Res 66(11):5867-5874 (Pubitemid 43927141)
25. Pennarun B, Meijer A, de Vries EG, Kleibeuker JH, Kruyt F, de Jong S (2010) Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta 1805(2):123-140
26. Galligan L, Longley DB, McEwan M, Wilson TR, McLaughlin K, Johnston PG (2005) Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther 4(12):2026-2036 (Pubitemid 43056986)
27. Johnston JB, Kabore AF, Strutinsky J, Hu X, Paul JT, Kropp DM, Kuschak B, Begleiter A, Gibson SB (2003) Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia. Oncogene 22(51):8356-8369 (Pubitemid 37485528)
28. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang HG, Zhang X, Bullrich F, Croce CM, Rai K, Hines J, Reed JC (1998) Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood 91(9):3379-3389 (Pubitemid 28193890)
29. Ewald B, Sampath D, Plunkett W (2008) Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 27(50):6522-6537
30. Solier S, Sordet O, Kohn KW, Pommier Y (2009) Death receptor-induced activation of the Chk2- and histone H2AX-associated DNA damage response pathways. Mol Cell Biol 29(1):68-82
31. Bosque A, Aguilo JI, del Rey M, Paz-Artal E, Allende LM, Naval J, Anel A (2008) Cell cycle regulation by FasL and Apo2L/TRAIL in human T-cell blasts. Implications for autoimmune lymphoproliferative syndromes. J Leukoc Biol 84(2):488-498
32. Nagaraj NS, Vigneswaran N, Zacharias W (2006) Cathepsin B mediates TRAIL-induced apoptosis in oral cancer cells. J Cancer Res Clin Oncol 132(3):171-183 (Pubitemid 43015778)
33. Vanden Berghe T, Linkermann A, Jouan-Lanhout S, Walczak H, Vandenabeele P (2014) Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol 15(2):135-147
34. Li LC, Liu GD, Zhang XJ, Li YB (2014) Autophagy, a novel target for chemotherapeutic intervention of thyroid cancer. Cancer Chemother Pharmacol 73(3):439-449
35. Galvani E, Peters GJ, Giovannetti E (2011) Thymidylate synthase inhibitors for non-small cell lung cancer. Expert Opin Investig Drugs 20(10):1343-1356
36. Temmink OH, de Bruin M, Comijn EM, Fukushima M, Peters GJ (2005) Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells. Anticancer Drugs 16(3):285-292 (Pubitemid 40283943)
37. Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, Kuwata K, Hoff PM (2006) Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer 107(6):1383-1390 (Pubitemid 44452789)
38. Doi T, Ohtsu A, Yoshino T, Boku N, Onozawa Y, Fukutomi A, Hironaka S, Koizumi W, Sasaki T (2012) Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer 107(3):429-434
39. Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A, Bray G, Mendelson D (2010) A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 16(4):1256-1263
40. Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R, Eskens FA, Loos WJ, de Vries EG, Sleijfer S (2009) Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res 15(17):5584-5590
41. Soria JC, Mark Z, Zatloukal P, Szima B, Albert I, Juhasz E, Pujol JL, Kozielski J, Baker N, Smethurst D, Hei YJ, Ashkenazi A, Stern H, Amler L, Pan Y, Blackhall F (2011) Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol 29(33):4442-4451